{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:54:07Z","timestamp":1781686447343,"version":"3.54.5"},"reference-count":52,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2013.0525","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T05:25:18Z","timestamp":1525238718000},"source":"Crossref","is-referenced-by-count":18,"title":["The Perioperative Management of Treatment With Anticoagulants and Platelet Aggregation Inhibitors"],"prefix":"10.3238","author":[{"given":"Axel","family":"Schlitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csilla","family":"J\u00e1mbor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Spannagl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke","family":"Gogarten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Zwi\u00dfler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2013,8,5]]},"reference":[{"key":"10.3238\/arztebl.2013.0525_ref1","doi-asserted-by":"crossref","unstructured":"Graham I, Atar D, Borch-Johnsen K, Boysen G, et al.: European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG). European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 2007; 28: 2375\u2013414.","DOI":"10.1093\/eurheartj\/ehm316"},{"key":"10.3238\/arztebl.2013.0525_ref2","doi-asserted-by":"crossref","unstructured":"Lahtela H, Rubboli A, Schlitt A, et al.: AFCAS. Heparin bridging vs. uninterrupted oral anticoagulation in patients with Atrial Fibrillation undergoing Coronary Artery Stenting. Results from the AFCAS registry. Circ J 2012; 76: 1363\u20138.","DOI":"10.1253\/circj.CJ-11-1206"},{"key":"10.3238\/arztebl.2013.0525_ref3","doi-asserted-by":"crossref","unstructured":"Camm AJ, Lip GYH, De Caterina R, et al.: 2012 focussed update of the ESC guidelines for the management of atrial fibrillation. Eur Heart J 2012; 33: 2719\u201347.","DOI":"10.1093\/eurheartj\/ehs253"},{"key":"10.3238\/arztebl.2013.0525_ref4","doi-asserted-by":"crossref","unstructured":"Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC: Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 2012; 126: 1630\u20139.","DOI":"10.1161\/CIRCULATIONAHA.112.105221"},{"key":"10.3238\/arztebl.2013.0525_ref5","unstructured":"Pausieren von oralen Antikoagulanzien bei Vorhofflimmern ist risikoreich. Arzneimittelbrief 2013; 47: 4\u20135."},{"key":"10.3238\/arztebl.2013.0525_ref6","doi-asserted-by":"crossref","unstructured":"Trappe HJ: Atrial fibrillation: established an innovative methods of evaluation and treatment. Dtsch Arztebl Int 2012; 109: 1\u20137.","DOI":"10.3238\/arztebl.2012.0001"},{"key":"10.3238\/arztebl.2013.0525_ref7","unstructured":"Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic Surgery (EACTS), Vahanian A, Alfieri O, Andreotti F, et al.: Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012; 33: 2451\u201396."},{"key":"10.3238\/arztebl.2013.0525_ref8","unstructured":"S3-Leitlinie Prophylaxe der ven\u00f6sen Thromboembolie (VTE). Version vom 18. M\u00e4rz 2009 Registrierungsnummer: 003\u2013001.www.awmf.org\/uploads\/tx_szleitlinien\/003\u2013001l_S3_Thromboembolie- Prophylaxe_2010.pdfAWMF."},{"key":"10.3238\/arztebl.2013.0525_ref9","doi-asserted-by":"crossref","unstructured":"Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G: American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 160\u201398.","DOI":"10.1378\/chest.08-0670"},{"key":"10.3238\/arztebl.2013.0525_ref10","doi-asserted-by":"crossref","unstructured":"Silber S, Albertsson P, Avil\u00e9s FF, et al.: Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26: 804\u201347.","DOI":"10.1016\/j.accreview.2005.08.063"},{"key":"10.3238\/arztebl.2013.0525_ref11","doi-asserted-by":"crossref","unstructured":"Hess CN, Becker RC, Alexander JH, Lopes RD: Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician. J Thromb Thrombolysis 2012; 34: 552\u201361.","DOI":"10.1007\/s11239-012-0785-8"},{"key":"10.3238\/arztebl.2013.0525_ref12","doi-asserted-by":"crossref","unstructured":"Raaz U, Maegdefessel L, Buerke M, Janusch M, Werdan K, Schlitt A: INR matters: a case on managing argatroban for bridging oral anticoagulation in a patient with heparin induced thrombocytopenia type II after mechanical heart valve replacement. Thromb Res 2009; 124: 242\u20133.","DOI":"10.1016\/j.thromres.2008.08.023"},{"key":"10.3238\/arztebl.2013.0525_ref13","doi-asserted-by":"crossref","unstructured":"Schellong SM, Haas S: Neue orale Antikoagulanzien und ihre Anwendung im perioperativen Umfeld. Anasthesiol Intensivmed Notfallmed Schmerzther 2012; 47: 266\u201372.","DOI":"10.1055\/s-0032-1310416"},{"key":"10.3238\/arztebl.2013.0525_ref14","doi-asserted-by":"crossref","unstructured":"Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M: Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573\u201379.","DOI":"10.1161\/CIRCULATIONAHA.111.029017"},{"key":"10.3238\/arztebl.2013.0525_ref15","doi-asserted-by":"crossref","unstructured":"Zhou W, Schwarting S, Illanes S, et al.: Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011; 42: 3594\u201399.","DOI":"10.1161\/STROKEAHA.111.624650"},{"key":"10.3238\/arztebl.2013.0525_ref16","doi-asserted-by":"crossref","unstructured":"Kaatz S, Kouides PA, Garcia DA, et al.: Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012; 87 Suppl 1: 141\u20135.","DOI":"10.1002\/ajh.23202"},{"key":"10.3238\/arztebl.2013.0525_ref17","doi-asserted-by":"crossref","unstructured":"Mega JL, Close SL, Wiviott SD, et al.: Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354\u201362.","DOI":"10.1056\/NEJMoa0809171"},{"key":"10.3238\/arztebl.2013.0525_ref18","doi-asserted-by":"crossref","unstructured":"Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al.: High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 2004; 25: 1903\u201310.","DOI":"10.1016\/j.ehj.2004.07.036"},{"key":"10.3238\/arztebl.2013.0525_ref19","doi-asserted-by":"crossref","unstructured":"Wiviott SD, Braunwald E, McCabe CH, et al.: Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001\u201315.","DOI":"10.1056\/NEJMoa0706482"},{"key":"10.3238\/arztebl.2013.0525_ref20","doi-asserted-by":"crossref","unstructured":"Bhatt DL: Prasugrel in clinical practice. N Engl J Med 2009; 361: 940\u20132.","DOI":"10.1056\/NEJMp0806848"},{"key":"10.3238\/arztebl.2013.0525_ref21","doi-asserted-by":"crossref","unstructured":"Wallentin L: P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 2009; 30: 1964\u201377.","DOI":"10.1093\/eurheartj\/ehp296"},{"key":"10.3238\/arztebl.2013.0525_ref22","doi-asserted-by":"crossref","unstructured":"Roe MT, Armstrong PW, Fox KA, et al.: TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012; 367: 1297\u2013309.","DOI":"10.1056\/NEJMoa1205512"},{"key":"10.3238\/arztebl.2013.0525_ref23","doi-asserted-by":"crossref","unstructured":"Wallentin L, Becker RC, Budaj A, et al.: Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2009; 361: 1045\u201357.","DOI":"10.1056\/NEJMoa0904327"},{"key":"10.3238\/arztebl.2013.0525_ref24","doi-asserted-by":"crossref","unstructured":"Teng R, Butler K: Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 2010; 66: 487\u201396.","DOI":"10.1007\/s00228-009-0778-5"},{"key":"10.3238\/arztebl.2013.0525_ref25","doi-asserted-by":"crossref","unstructured":"Giannitsis E, Katus HA: Antiplatelet therapy\u2014ticagrelor. Hamostaseologie 2012; 32: 177\u201385.","DOI":"10.5482\/HAMO-12-05-0003"},{"key":"10.3238\/arztebl.2013.0525_ref26","doi-asserted-by":"crossref","unstructured":"Burger W, Chemnitius JM, Kneissl GD, Rucker G: Low-dose aspirin for secondary cardiovascular prevention\u2014cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation \u2013 review and meta-analysis. J Intern Med 2005; 257: 399\u2013414.","DOI":"10.1111\/j.1365-2796.2005.01477.x"},{"key":"10.3238\/arztebl.2013.0525_ref27","unstructured":"Poldermans D, Bax JJ, Boersma E, et al.: Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: The Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA). Eur Heart J 2009; 30: 2769\u2013812."},{"key":"10.3238\/arztebl.2013.0525_ref28","doi-asserted-by":"crossref","unstructured":"Wolff T, Miller T, Ko S: Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 150: 405\u201310.","DOI":"10.7326\/0003-4819-150-6-200903170-00009"},{"key":"10.3238\/arztebl.2013.0525_ref29","doi-asserted-by":"crossref","unstructured":"Korte W, Cattaneo M, Chassot PG, et al.: Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on Perioperative Coagulation of the Austrian Society for Anesthesiology, Resuscitation and Intensive Care (OGARI) and the Working Group Thrombosis of the European Society for Cardiology (ESC). Thromb Haemost 2011; 105: 743\u20139.","DOI":"10.1160\/TH10-04-0217"},{"key":"10.3238\/arztebl.2013.0525_ref30","unstructured":"Gogarten W, Van Aken H, B\u00fcttner J, Riess H, Wulf H, B\u00fcrkle H: R\u00fcckenmarksnahe Regionalan\u00e4sthesien und Thromboembolieprophylaxe\/antithrombotische Medikation. 2nd revised recommendation der Deutschen Gesellschaft f\u00fcr An\u00e4sthesiologie und Intensivmedizin. An\u00e4sth Intensivmedizin 2007; 48: 109\u201324."},{"key":"10.3238\/arztebl.2013.0525_ref31","doi-asserted-by":"crossref","unstructured":"Grines CL, Bonow RO, Casey DE, et al.: Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 2007; 49: 734\u20139.","DOI":"10.1161\/CIRCULATIONAHA.106.180944"},{"key":"10.3238\/arztebl.2013.0525_ref32","doi-asserted-by":"crossref","unstructured":"Vicenzi MN, Meislitzer T, Heitzinger B, Halaj M, Fleisher LA, Metzler H: Coronary artery stenting and non-cardiac surgery-a prospective outcome study. Br J Anaesth 2006; 96: 686\u201393.","DOI":"10.1093\/bja\/ael083"},{"key":"10.3238\/arztebl.2013.0525_ref33","doi-asserted-by":"crossref","unstructured":"Bonzel T, Erbel R, Hamm CW, et al.: Perkutane Koronarinterventionen (PCI). Clin Res Cardiol 2008; 97: 513\u201347.","DOI":"10.1007\/s00392-008-0697-y"},{"key":"10.3238\/arztebl.2013.0525_ref34","doi-asserted-by":"crossref","unstructured":"Iakovou I, Schmidt T, Bonizzoni E, et al.: Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126\u201330.","DOI":"10.1001\/jama.293.17.2126"},{"key":"10.3238\/arztebl.2013.0525_ref35","doi-asserted-by":"crossref","unstructured":"Newsome LT, Kutcher MA, Royster RL: Coronary artery stents: Part I. Evolution of percutaneous coronary intervention. Anesth Analg 2008; 107: 552\u201369.","DOI":"10.1213\/ane.0b013e3181732049"},{"key":"10.3238\/arztebl.2013.0525_ref36","doi-asserted-by":"crossref","unstructured":"Schouten O, van Domburg RT, Bax JJ, et al.: Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. J Am Coll Cardiol 2007; 49: 122\u20134.","DOI":"10.1016\/j.jacc.2006.10.004"},{"key":"10.3238\/arztebl.2013.0525_ref37","doi-asserted-by":"crossref","unstructured":"Stettler C, Wandel S, Allemann S, et al.: Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007; 370: 937\u201348.","DOI":"10.1016\/S0140-6736(07)61444-5"},{"key":"10.3238\/arztebl.2013.0525_ref38","doi-asserted-by":"crossref","unstructured":"Rhee SJ, Yun KH, Lee SR, Chae JK, Nam CW, Jun DH, Jeong JW: Drug-eluting stent thrombosis during perioperative period. Int Heart J 2008; 49: 135\u201342.","DOI":"10.1536\/ihj.49.135"},{"key":"10.3238\/arztebl.2013.0525_ref39","doi-asserted-by":"crossref","unstructured":"Wilson SH, Fasseas P, Orford JL, Lennon RJ, Horlocker T, Charnoff NE, Melby S, Berger PB: Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll Cardiol 2003; 42: 234\u201340.","DOI":"10.1016\/S0735-1097(03)00622-3"},{"key":"10.3238\/arztebl.2013.0525_ref40","doi-asserted-by":"crossref","unstructured":"Hamm CW, Bassand JP, Agewall S, et al.: ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999\u20133054.","DOI":"10.1093\/eurheartj\/ehr236"},{"key":"10.3238\/arztebl.2013.0525_ref41","doi-asserted-by":"crossref","unstructured":"Fleisher LA, Beckman JA, Brown KA, et al.: ACC\/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Anesth Analg 2008; 106: 685\u2013712.","DOI":"10.1213\/01\/ane.0000309024.28586.70"},{"key":"10.3238\/arztebl.2013.0525_ref42","doi-asserted-by":"crossref","unstructured":"Rade JJ, Hogue CW, Jr.: Noncardiac surgery for patients with coronary artery stents: timing is everything. Anesthesiology 2008; 109: 573\u20135.","DOI":"10.1097\/ALN.0b013e3181870a4b"},{"key":"10.3238\/arztebl.2013.0525_ref43","doi-asserted-by":"crossref","unstructured":"Sharma AK, Ajani AE, Hamwi SM, Maniar P, Lakhani SV, Waksman R, Lindsay J: Major noncardiac surgery following coronary stenting: when is it safe to operate? Catheter Cardiovasc Interv 2004; 63: 141\u20135.","DOI":"10.1002\/ccd.20124"},{"key":"10.3238\/arztebl.2013.0525_ref44","doi-asserted-by":"crossref","unstructured":"Levi M: Emergency reversal of antithrombotic treatment. Intern Emerg Med 2009; 4: 137\u201345.","DOI":"10.1007\/s11739-008-0201-8"},{"key":"10.3238\/arztebl.2013.0525_ref45","doi-asserted-by":"crossref","unstructured":"Pearse RM, Moreno RP, Bauer P, et al.: European Surgical Outcomes Study (EuSOS) group for the Trials groups of the European Society of Intensive Care Medicine and the European Society of Anaesthesiology. Mortality after surgery in Europe: a 7 day cohort study. Lancet 2012; 380: 1059\u201365.","DOI":"10.1016\/S0140-6736(12)61148-9"},{"key":"10.3238\/arztebl.2013.0525_ref46","doi-asserted-by":"crossref","unstructured":"Douketis JD, Berger PB, Dunn AS, Jaffer AK, Spyropoulos AC, Becker RC, Ansell J: The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 299\u2013339.","DOI":"10.1378\/chest.08-0675"},{"key":"10.3238\/arztebl.2013.0525_ref47","doi-asserted-by":"crossref","unstructured":"Gogarten W, Van Aken HK: Perioperative Thromboseprophylaxe \u2013 Thrombozytenaggregationshemmer \u2013 Bedeutung f\u00fcr die An\u00e4sthesie. Anasthesiol Intensivmed Notfallmed Schmerzther 2012; 47: 242\u201351; quiz 52.","DOI":"10.1055\/s-0032-1310414"},{"key":"10.3238\/arztebl.2013.0525_ref48","doi-asserted-by":"crossref","unstructured":"Gogarten W, Vandermeulen E, van Aken H, Kozek S, Llau JV, Samama CM: Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol 2010; 27: 999\u20131015.","DOI":"10.1097\/EJA.0b013e32833f6f6f"},{"key":"10.3238\/arztebl.2013.0525_ref49","doi-asserted-by":"crossref","unstructured":"J\u00e1mbor C, Spannagl M, Zwissler B: Perioperatives Management von Patienten mit Koronarstents bei nichtherzchirurgischen Eingriffen. Anaesthesist 2009; 58: 971\u201385.","DOI":"10.1007\/s00101-009-1628-7"},{"key":"10.3238\/arztebl.2013.0525_ref50","doi-asserted-by":"crossref","unstructured":"Savonitto S, D\u2019Urbano M, Caracciolo M, Barlocco F, Mariani G, Nichelatti M, Klugmann S, De Servi S: Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of \u2019bridging\u2019 antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth 2010; 104: 285\u201391.","DOI":"10.1093\/bja\/aep373"},{"key":"10.3238\/arztebl.2013.0525_ref51","doi-asserted-by":"crossref","unstructured":"Brilakis ES, Banerjee S, Berger PB: Perioperative management of patients with coronary stents. J Am Coll Cardiol 2007; 49: 2145\u201350.","DOI":"10.1016\/j.jacc.2007.02.046"},{"key":"10.3238\/arztebl.2013.0525_ref52","doi-asserted-by":"crossref","unstructured":"Metzler H, Huber K, Kozek-Langenecker S, Vicenzi MN, Munch A: Koronare Stents, duale Antipl\u00e4ttchentherapie und die perioperative Problematik. Anaesthesist 2007; 56: 401\u201310.","DOI":"10.1007\/s00101-007-1171-3"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2013.0525","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T08:56:09Z","timestamp":1638780969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2013.0525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,5]]},"references-count":52,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2013.0525","relation":{"is-cited-by":[{"id-type":"doi","id":"10.1007\/s00129-017-4024-4","asserted-by":"object"}]},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,5]]}}}